Clinical results of and prospects for the use of controlled-release antiepileptic drugs: a new once-daily levetiracetam formulation
Many antiepileptic drugs (AEDs) have a short half-life (T1/2) with a wide fluctuation from peak to trough blood concentrations. According to this pharmacokinetic profile, there may be both adverse events (AEs) due to the increase in a blood drug concentrations and seizures as a result of its fall, w...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2017-11-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/780 |
| _version_ | 1797876465888395264 |
|---|---|
| author | P. N. Vlasov |
| author_facet | P. N. Vlasov |
| author_sort | P. N. Vlasov |
| collection | DOAJ |
| description | Many antiepileptic drugs (AEDs) have a short half-life (T1/2) with a wide fluctuation from peak to trough blood concentrations. According to this pharmacokinetic profile, there may be both adverse events (AEs) due to the increase in a blood drug concentrations and seizures as a result of its fall, which ultimately lowers patient adherence to therapy.Pharmaceutical technologies ensuring a delayed release of the active ingredient can make the concentration of a drug more stable and therefore reduce the frequency and severity of AEs, enhance the efficiency of therapy, compliance, and retention of the patient on AEDs. The emergence of a new sustained-release levetiracetam formulation in neurologists' practice greatly enhances the possibilities of epilepsy therapy. |
| first_indexed | 2024-04-10T02:02:36Z |
| format | Article |
| id | doaj.art-faf1c4b04aab4f27921f8f07dda8b366 |
| institution | Directory Open Access Journal |
| issn | 2074-2711 2310-1342 |
| language | Russian |
| last_indexed | 2024-04-10T02:02:36Z |
| publishDate | 2017-11-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Неврология, нейропсихиатрия, психосоматика |
| spelling | doaj.art-faf1c4b04aab4f27921f8f07dda8b3662023-03-13T08:42:17ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422017-11-01939810410.14412/2074-2711-2017-3-98-104682Clinical results of and prospects for the use of controlled-release antiepileptic drugs: a new once-daily levetiracetam formulationP. N. Vlasov0A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia; Moscow Regional Research Institute of Obstetrics and GynecologyMany antiepileptic drugs (AEDs) have a short half-life (T1/2) with a wide fluctuation from peak to trough blood concentrations. According to this pharmacokinetic profile, there may be both adverse events (AEs) due to the increase in a blood drug concentrations and seizures as a result of its fall, which ultimately lowers patient adherence to therapy.Pharmaceutical technologies ensuring a delayed release of the active ingredient can make the concentration of a drug more stable and therefore reduce the frequency and severity of AEs, enhance the efficiency of therapy, compliance, and retention of the patient on AEDs. The emergence of a new sustained-release levetiracetam formulation in neurologists' practice greatly enhances the possibilities of epilepsy therapy.https://nnp.ima-press.net/nnp/article/view/780epilepsyantiepileptic drugspharmacokineticsefficacytolerabilityadverse eventstherapy adherencelevetiracetam |
| spellingShingle | P. N. Vlasov Clinical results of and prospects for the use of controlled-release antiepileptic drugs: a new once-daily levetiracetam formulation Неврология, нейропсихиатрия, психосоматика epilepsy antiepileptic drugs pharmacokinetics efficacy tolerability adverse events therapy adherence levetiracetam |
| title | Clinical results of and prospects for the use of controlled-release antiepileptic drugs: a new once-daily levetiracetam formulation |
| title_full | Clinical results of and prospects for the use of controlled-release antiepileptic drugs: a new once-daily levetiracetam formulation |
| title_fullStr | Clinical results of and prospects for the use of controlled-release antiepileptic drugs: a new once-daily levetiracetam formulation |
| title_full_unstemmed | Clinical results of and prospects for the use of controlled-release antiepileptic drugs: a new once-daily levetiracetam formulation |
| title_short | Clinical results of and prospects for the use of controlled-release antiepileptic drugs: a new once-daily levetiracetam formulation |
| title_sort | clinical results of and prospects for the use of controlled release antiepileptic drugs a new once daily levetiracetam formulation |
| topic | epilepsy antiepileptic drugs pharmacokinetics efficacy tolerability adverse events therapy adherence levetiracetam |
| url | https://nnp.ima-press.net/nnp/article/view/780 |
| work_keys_str_mv | AT pnvlasov clinicalresultsofandprospectsfortheuseofcontrolledreleaseantiepilepticdrugsanewoncedailylevetiracetamformulation |